Advances in CAR T-Cell Therapy and Cancer Treatment Highlighted by Kite at Major 2024 ConferencesKite’s Presentations at EHA 2024 Emphasize Positive Patient Outcomes and CAR T-Cell Therapy Delivery
SANTA MONICA, Calif. ’ Kite, a Gilead Company (NASDAQ: GILD), has announced the presentation of 12 abstracts from its leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress. Scheduled for June 13-16 in Madrid, Spain, these presentations aim to showcase significant advancements and patient outcomes in CAR T-cell therapy.
Among the abstracts, four will highlight real-world data concerning Yescarta (axicabtagene ciloleucel), particularly in the manufacturing process for patients suffering from relapsed/refractory (R/R) large B-cell lymphoma (LBCL). These insights are expected to contribute to optimizing Yescarta production and delivery, ultimately leading to enhanced treatment efficacy and patient experience.Ongoing Progress in Anito-Cel Multiple Myeloma Program with Arcellx
In addition to the EHA presentations, Kite, in partnership with Arcellx, Inc. (NASDAQ: ACLX), has made significant strides in the anitocabtagene autoleucel (anito-cel) program targeting multiple myeloma. Noteworthy for being the first BCMA CAR T-cell therapy to incorporate Arcellx’s innovative D-Domain binder, anito-cel has shown promise in early clinical trials.
The companies have detailed plans for a global, Phase 3 randomized controlled trial named iMMagine-3, which aims to further evaluate the efficacy and safety of anito-cel in multiple myeloma patients. These ambitious steps underscore the collaborative effort to bring novel CAR T-cell therapies to market, providing new hope for patients with this challenging cancer.Broad Array of Oncology Developments to be Highlighted at ASCO 2024
FOSTER CITY, Calif. & SANTA MONICA, Calif. ’ Gilead Sciences, Inc. and Kite are set to present 18 abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring their comprehensive and diverse approach to oncology research and treatment.
These presentations will span a wide range of cancer types, including not only hematologic malignancies like leukemia and lymphoma but also solid tumors such as those found in lung, breast, gastrointestinal, and colorectal cancers. Among the key data to be shared are new insights about Trodelvy, a therapy targeting multiple tumor types, further solidifying Gilead and Kite’s commitment to transforming current cancer treatment paradigms.Conclusion
Kite’s robust presence at both the EHA and ASCO 2024 conferences highlights its ongoing dedication to innovating and improving cancer treatment. By driving forward with new research, clinical trials, and real-world data analyses, Kite and its partners are making significant strides in the fight against various forms of cancer, heralding a new era of hope for patients worldwide.
Comments